文献速递主动脉外科

全球注册研究:扩展性胸主动脉腔内修复治疗B型主动脉夹层的 outcomes

Outcomes following extended thoracic endovascular aortic repair for Type B aortic dissection from the global registry for endovascular aortic treatment.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本研究基于全球主动脉腔内治疗注册数据库,评估扩展性胸主动脉腔内修复(TEVAR)治疗B型主动脉夹层的短期至长期安全性和有效性。共170例手术,其中78例(46%)为扩展性治疗(置入>1枚支架)。结果显示扩展性与非扩展性治疗在院内脊髓缺血、死亡率及1年和5年并发症、囊腔扩张、破裂和全因死亡率方面均无显著差异。

要点

  • 扩展性TEVAR治疗B型夹层未增加院内脊髓缺血和死亡风险。
  • 扩展性与非扩展性治疗的1年和5年并发症及再干预率相似。
  • 扩展性治疗组囊腔扩张和破裂风险在1年和5年时无统计学差异。

核心结论

  • 扩展性TEVAR治疗B型主动脉夹层可能与相似的手术相关风险和并发症相关。
  • 未来需更大规模研究明确哪些患者可能从扩展性治疗中获益。

研究设计与样本

  • 基于全球主动脉腔内治疗注册数据库(Global Registry for Endovascular Aortic Treatment)的回顾性研究。
  • 纳入2010至2016年急性及亚急性B型主动脉夹层患者。
  • 按治疗范围分层:非扩展组(置入1枚支架)和扩展组(置入>1枚支架)。
  • 共170例手术,其中78例(46%)为扩展治疗,中位置入2枚支架(范围2-5枚)。
  • 主要终点为院内脊髓缺血和死亡率;次要终点包括手术相关并发症、囊腔动态、破裂及1年和5年全因死亡率。

主要发现

  • 扩展组与非扩展组复杂表现发生率相似(53% vs 64%;P=0.13)。
  • 院内脊髓缺血发生率相似(2.6% vs 2.2%;P=1),院内死亡率相似(2.6% vs 2.2%;P=1)。
  • 囊腔扩张率:1年14% vs 23%(P=0.80),5年16% vs 32%(P=0.29)。
  • 破裂风险:1年1.3% vs 3.3%(P=0.63)。
  • 全因死亡率:1年10% vs 7.6%(P=0.54),5年19% vs 21%(P=0.82)。

关键数值与推荐

  • 扩展性治疗定义为置入>1枚支架。
  • 非扩展性治疗定义为置入1枚支架。
  • 主要终点为院内脊髓缺血和死亡率。

临床怎么用

  • 对于B型主动脉夹层,扩展性TEVAR(置入多枚支架)在短期至中期随访中未显示增加脊髓缺血、死亡或并发症风险。
  • 临床决策时可考虑在必要时使用扩展性TEVAR,但需个体化评估获益人群。

局限性

  • 回顾性注册研究设计,可能存在选择偏倚。
  • 样本量有限(170例),扩展组仅78例,统计效能可能不足。
  • 未来需更大规模研究确定扩展性治疗的适应人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study evaluated the short- to longer-term safety and efficacy of extended thoracic endovascular aortic repair for Type B aortic dissection. METHODS: We identified acute and subacute Type B dissection between 2010 and 2016 in the Global Registry for Endovascular Aortic Treatment. We stratified the population based on treatment extent: 'non-extended' (1 stent graft deployed), 'extended' (>1 stent graft deployed). Our primary outcomes were in-hospital spinal cord ischaemia and mortality. Secondarily, we evaluated procedure-related complications (endoleak, migration, fracture, compression, reinterventions), sac dynamics, rupture, and all-cause mortality at 1 and 5 years. Sensitivity analysis was performed in patients without prior aortic procedures. RESULTS: Of 170 procedures, 78 (46%) were extended (median 2 [range 2-5] stent-grafts). Extended and non-extended treatment had similar rates of complicated presentations (53% vs 64%; P = 0.13). Compared with non-extended treatment, extended treatment had similar in-hospital rates of spinal cord ischaemia (2.6% vs 2.2%; P = 1) and mortality (2.6% vs 2.2%, P = 1). Additionally, extended treatment had not statistically different sac expansion rates, (1 year: 14% vs 23%, P =0.80; 5 years: 16% vs 32%, P=0.29) and rupture risk (1 year: 1.3% vs 3.3%, P = 0.63), similar procedure-related complications (endoleak, migration, fracture, compression, reinterventions; all P > 0.05) and all-cause mortality (1 year: 10% vs 7.6%, P=0.54; 5 years: 19% vs 21%, P=0.82). All outcomes remained similar on sensitivity analysis. CONCLUSIONS: Our findings suggest that extended treatment for Type B aortic dissection may be associated with similar procedure-related risks and complications. Future larger studies are needed to define who might benefit from an extended treatment and further optimize patient-specific treatment for aortic dissection.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Allievi S, Mandigers TJ, Weaver FA, et al. Outcomes following extended thoracic endovascular aortic repair for Type B aortic dissection from the global registry for endovascular aortic treatment. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40674576. doi:10.1093/icvts/ivaf156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。